Northern California Retina Vitreous Associates

Summary

Northern California Retina Vitreous Associates is a medical facility located in Mountain View, California. This center is recognized for care of Macular Degeneration, Age-Related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Degeneration and other specialties. Northern California Retina Vitreous Associates is involved with conducting 67 clinical trials across 35 conditions. There are 1 research doctors associated with this hospital, such as Mountain View Site PI.

Top PIs

Clinical Trials running at Northern California Retina Vitreous Associates

Macular Degeneration

Age-Related Macular Degeneration

Diabetic Macular Edema

Choroidal Neovascularization

Choroidal neovascularization

Retinal Degeneration

Retinal Disease

None

Wet AMD

4D-150 + EYLEA

for Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Recruiting

2 awards

Phase 3

4 criteria

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). The typical treatment for nAMD is frequent injections of anti-VEGF therapy. Researchers are testing ABBV-RGX-314 to see if it has similar effects as the current approved standard of care, such as Lucentis® or Eylea® injections. The duration of this study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314 after week 52, up to 80 weeks post-randomization. The primary outcome measure for this investigational study is to evaluate the mean change in best-corrected visual acuity (BCVA) for ABBV-RGX-314 compared with ranibizumab monthly at the Week 40 visit.

Recruiting

1 award

Phase 2

4 criteria

Pozelimab + Cemdisiran

for Macular Degeneration

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Recruiting

1 award

Phase 3

3 criteria